Terms: = Prostate cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Treatment
484 results:
1. Regulation of Molecular Biomarkers Associated with the Progression of prostate cancer.
Martin-Caraballo M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673756
[TBL] [Abstract] [Full Text] [Related]
2. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant prostate cancer.
Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling the Anticancer Potential of Pasak Bumi (Eurycoma Longifolia Jack) Root Extract in prostate cancer treatment.
Rahman EY; Kania N; Sutapa H; Purnomo AF; Panghiyangani R; Skripsiana NS
Med Arch; 2024; 78(2):117-121. PubMed ID: 38566865
[TBL] [Abstract] [Full Text] [Related]
4. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
5. Real-World Overall Survival and treatment Patterns by
Gupta S; To TM; Graf R; Kadel EE; Reilly N; Albarmawi H
JCO Precis Oncol; 2024 Mar; 8():e2300562. PubMed ID: 38547419
[TBL] [Abstract] [Full Text] [Related]
6. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
7. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
8. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
[TBL] [Abstract] [Full Text] [Related]
9. Capivasertib: First Approval.
Shirley M
Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
[TBL] [Abstract] [Full Text] [Related]
10. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
11. Pholiotic acid promotes apoptosis in human metastatic melanoma cells.
Avola R; Graziano ACE; Madrid A; Clericuzio M; Cardile V; Russo A
Chem Biol Interact; 2024 Feb; 390():110894. PubMed ID: 38301881
[TBL] [Abstract] [Full Text] [Related]
12. Combined Cabazitaxel and Carboplatin treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
13. Mechanism of Antitumor Effects of Saffron in Human prostate cancer Cells.
Khan M; Hearn K; Parry C; Rasid M; Brim H; Ashktorab H; Kwabi-Addo B
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201944
[TBL] [Abstract] [Full Text] [Related]
14. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
15. The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol.
Basso J; de Lima JB; Bessel M; Tobar Leitão SA; Machado Baptista T; Roithmann S; Franco Carvalhal E; da Silva Schmitt C; Morzoletto Pedrollo I; Schuch A; Atalibio Hartmann A; Neubarth Estivallet CL; Behrend Silva Ribeiro G; Zordan RA; Isaacsson Velho P
BMC Urol; 2023 Dec; 23(1):208. PubMed ID: 38082337
[TBL] [Abstract] [Full Text] [Related]
16. prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
[TBL] [Abstract] [Full Text] [Related]
17. Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
O'Malley DE; Raspin K; Melton PE; Burdon KP; Dickinson JL; FitzGerald LM
Br J Cancer; 2024 Feb; 130(3):347-357. PubMed ID: 37945750
[TBL] [Abstract] [Full Text] [Related]
18. The Role of microRNAs in Regulating cancer Cell Response to Oxaliplatin-Containing Regimens.
Tavakoli Pirzaman A; Ebrahimzadeh Pirshahid M; Babajani B; Rahmati A; Niknezhad S; Hosseinzadeh R; Taheri M; Ebrahimi-Zadeh F; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231206003. PubMed ID: 37849311
[TBL] [Abstract] [Full Text] [Related]
19. prostate cancer Stem Cells: Biology and treatment Implications.
Koukourakis IM; Platoni K; Kouloulias V; Arelaki S; Zygogianni A
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834336
[TBL] [Abstract] [Full Text] [Related]
20. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract] [Full Text] [Related]
[Next]
